Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients
Status:
Completed
Trial end date:
2017-06-16
Target enrollment:
Participant gender:
Summary
This is a prospective, Phase 1-2, single center study in a total of 100 subjects with
Neuroendocrine Tumors (NETs). Study participants will receive a one-time administration of
68Ga-DOTATATE and undergo a PET/CT imaging study, to investigate its suitability as a PET
imaging agent for NETs.